IO Biotech Inc
NASDAQ:IOBT
Intrinsic Value
IO Biotech, Inc. is a clinical stage biotechnology company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of IOBT.
IO Biotech Inc's market capitalization is 95.4m USD.
IOBT stock price is 1.4478 USD.
IOBT.
IOBT. Open DCF Valuation
IOBT. Open Relative Valuation
IOBT has upside potential of 464% compared to the average analyst price target.
Open Wall St Estimates
IOBT has negative Free Cash Flow for the last twelve months.
IOBT has negative Operating Income for the last twelve months.
IOBT has negative Net Income for the last twelve months.
IOBT's ROE (Return on Equity) for the past 12 months is negative and is equal to -63%.
IOBT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -2 088%.
IOBT has negative three-year average ROE (Return on Equity): -52%. The company is not efficient at transforming stockholders' equity into net income.
IOBT has negative three-year average ROIC (Return on Invested Capital): -1 205%. The company is not efficient at using invested capital to generate operating income.
IOBT's short-term assets (147m USD) exceed its short-term liabilties (16m USD).
IOBT's long-term assets (151m USD) exceed its long-term liabilties (18m USD).
IOBT's D/E (Debt to Equity) is very low and is equal to 0.
IOBT's Altman Z-Score is very low and is equal to -0.31.
Fundamental Analysis
IO Biotech Inc
Balance Sheet Decomposition
IO Biotech Inc
| Current Assets | 147.3m |
| Cash & Short-Term Investments | 143.2m |
| Receivables | 1.1m |
| Other Current Assets | 2.9m |
| Non-Current Assets | 3.5m |
| PP&E | 3.1m |
| Other Non-Current Assets | 357k |
| Current Liabilities | 15.7m |
| Accounts Payable | 3.9m |
| Accrued Liabilities | 11m |
| Other Current Liabilities | 806k |
| Non-Current Liabilities | 1.8m |
| Other Non-Current Liabilities | 1.8m |
Earnings Waterfall
IO Biotech Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-91.4m
USD
|
|
Operating Income
|
-91.4m
USD
|
|
Other Expenses
|
5.4m
USD
|
|
Net Income
|
-86.1m
USD
|
Free Cash Flow Analysis
IO Biotech Inc
IOBT Profitability Score
Profitability Due Diligence
IO Biotech Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
IO Biotech Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
IOBT Solvency Score
Solvency Due Diligence
IO Biotech Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
IO Biotech Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IOBT Price Targets Summary
IO Biotech Inc
According to Wall Street analysts, the average 1-year price target for
IOBT
is 8.16 USD
with a low forecast of 5.05 USD and a high forecast of 10.5 USD.
Ownership
IOBT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
IOBT Price
IO Biotech Inc
| Average Annual Return | -57.64% |
| Standard Deviation of Annual Returns | 12.11% |
| Max Drawdown | -95% |
| Market Capitalization | 95.4m USD |
| Shares Outstanding | 65 880 900 |
| Percentage of Shares Shorted | 0.13% |
Company Profile
IO Biotech Inc
Country
Industry
Market Cap
Dividend Yield
Description
IO Biotech, Inc. is a clinical stage biotechnology company. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
You don't have any saved screeners yet
